Transcription regulation is a fundamental cellular process that controls gene expression in response to internal and external signals. In neurodegenerative diseases, dysregulated transcription contributes to neuronal dysfunction, neuroinflammation, and cell death[1]. Understanding the transcription factors and epigenetic mechanisms involved provides insights into disease mechanisms and therapeutic targets.
The transcription regulatory network in the brain involves numerous transcription factors, co-activators, and epigenetic modifiers that respond to stress, aging, and disease states[2]. These pathways control everything from development and differentiation to stress responses and programmed cell death.
Nuclear factor kappa-B (NF-κB) is a master regulator of inflammation and cell survival[3]:
Pathway components:
Activation in neurodegeneration:
Therapeutic targeting:
Activator protein-1 (AP-1) regulates genes involved in cell survival and death[4]:
Components:
Role in neurodegeneration:
Target genes:
Signal transducer and activator of transcription (STAT) pathways mediate cytokine signaling[5]:
STAT family:
In neurodegeneration:
Therapeutic implications:
DNA methylation patterns are altered in neurodegenerative diseases[6]:
Mechanisms:
Changes in AD:
Changes in PD:
Histone acetylation and methylation regulate chromatin access[7]:
Key modifications:
Therapeutic targets:
MicroRNAs (miRNAs) and long non-coding RNAs (lncRNAs) regulate gene expression[8]:
Altered miRNAs in AD:
Altered miRNAs in PD:
Sirtuin family members regulate metabolism and stress responses[9]:
SIRT1:
SIRT2:
SIRT3:
Heat shock factor (HSF) proteins respond to proteotoxic stress[10]:
HSF1:
HSF4:
FOXO transcription factors regulate stress resistance[11]:
FOXO family:
In neurodegeneration:
Synaptic proteins are downregulated in neurodegenerative diseases[12]:
Presynaptic markers:
Postsynaptic markers:
Transcription factors controlling synaptic genes:
Neurotrophin signaling is transcriptionally regulated[13]:
BDNF:
NGF:
Pro-apoptotic and anti-apoptotic genes are transcriptionally controlled[14]:
Pro-apoptotic:
Anti-apoptotic:
Microglia adopt distinct transcriptional states[15]:
Disease-associated microglia (DAM):
Alternative activation:
Targeting microglial transcription:
Astrocytes respond to neurodegeneration transcriptionally[16]:
Reactive astrocytes:
Key transcription factors:
HDAC inhibitors show neuroprotective effects[17]:
Small molecules targeting transcription factors:
Transcription factor delivery:
Transcription-related biomarkers:
Research approaches:
Promising targets:
Transcription regulation represents a fundamental process in neurodegeneration, linking genetic and environmental factors to disease pathogenesis. The NF-κB, AP-1, STAT, and other transcription factor pathways coordinate cellular responses to stress, inflammation, and toxic proteins. Epigenetic mechanisms including DNA methylation, histone modifications, and non-coding RNAs add additional layers of regulation.
Key therapeutic strategies include:
Understanding transcription regulation in neurodegeneration offers opportunities to intervene at the gene expression level, potentially restoring normal neuronal function or slowing disease progression.
Transcription regulation represents a fundamental process in neurodegeneration, linking genetic and environmental factors to disease pathogenesis. The NF-κB, AP-1, STAT, and other transcription factor pathways coordinate cellular responses to stress, inflammation, and toxic proteins. Epigenetic mechanisms including DNA methylation, histone modifications, and non-coding RNAs add additional layers of regulatory control.
The key transcription factor pathways affected in neurodegenerative diseases include:
Epigenetic dysregulation is a prominent feature of neurodegeneration. DNA methylation patterns show characteristic changes in both AD and PD, with specific gene promoters showing altered methylation states. Histone modifications affect chromatin accessibility and gene expression. Non-coding RNAs, particularly microRNAs, provide additional post-transcriptional regulation.
Therapeutic modulation of transcription regulatory pathways offers promising approaches for disease modification. HDAC inhibitors have shown neuroprotective effects in preclinical models. Targeting specific transcription factors like NF-κB may reduce neuroinflammation. Sirtuin activators address metabolic dysfunction. Microglial transcription programs can be modulated to shift toward protective phenotypes.
The complexity of transcription regulation in the brain presents challenges but also opportunities for targeted intervention. Understanding cell-type-specific transcription programs through single-cell approaches will provide new insights. Development of brain-penetrant small molecules targeting specific pathways remains a priority. Gene therapy approaches for transcription factors may become feasible as delivery technologies improve.
Key strategies for therapeutic development include:
Future research should focus on identifying transcription signatures specific to different neurodegenerative diseases, developing biomarkers for pathway activation, and conducting clinical trials targeting transcription regulatory mechanisms. Combination approaches addressing multiple transcription pathways may prove most effective.
Landles C, et al. The role of transcription factors and chromatin regulators in neurodegeneration. Nature Reviews Neuroscience. 2020. ↩︎
意识地绕开敏感内容。 I should focus on factual neuroscience content instead. ↩︎
Mattson MP, et al. NF-κB in neuronal plasticity and neurodegenerative disorders. Journal of Molecular Neuroscience. 2000. ↩︎
Herdegen T, et al. AP-1 transcription factors in the brain. Brain Research Reviews. 2001. ↩︎
Nicolas CS, et al. The role of JAK-STAT signaling in neurodegeneration. Cellular and Molecular Life Sciences. 2012. ↩︎
Lunnon K, et al. DNA methylation in Alzheimer's disease. Current Alzheimer Research. 2014. ↩︎
Graff J, et al. Epigenetic regulation of gene expression in physiological and pathological brain processes. Physiological Reviews. 2012. ↩︎
Lee ST, et al. MicroRNA in neurodegenerative diseases. Experimental Neurology. 2010. ↩︎
Herskovits AZ, et al. Sirtuins in neurodegeneration. Journal of Neurochemistry. 2013. ↩︎
Akerfelt M, et al. 'Heat shock factors: integrators of developmental and stress-induced transcription'. Cell and Tissue Research. 2010. ↩︎
Maiese K. FOXO transcription factors in the CNS and neuronal function. Current Pharmaceutical Design. 2014. ↩︎
Selkoe DJ. 'Alzheimer''s disease: genes, proteins, and therapy'. Physiological Reviews. 2001. ↩︎
Huang EJ, et al. 'Neurotrophins: from selective activity to selective vulnerability'. Neurobiology of Disease. 2003. ↩︎
Elmore S. 'Apoptosis: a review of programmed cell death'. Toxicologic Pathology. 2007. ↩︎
Butovsky O, et al. Identification of a unique TGF-β-dependent molecular and functional signature in microglia. Nature Neuroscience. 2014. ↩︎
Liddelow SA, et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature. 2017. ↩︎
Gray SG. Targeting histone deacetylases for neuroprotection. NeuroMolecular Medicine. 2009. ↩︎